tion in combination with MMF and delayed introduction of CsA, in the absence of Cs, is not well tolerated Background. Despite their well-known side-effects, corticosteroids (Cs) are currently used after kidney in recipients of kidney transplants. An earlier introduction of calcineurin inhibitors and/or a shorter course transplantation. Avoidance of Cs may improve patient quality of life and eventual long-term survival. We of ATG may reduce the incidence of fever and serum sickness secondary to ATG. report on a regimen using antithymocyte globulin (ATG) and mycophenolate mofetil (MMF ) for induc-
Introduction
(1.5 mg/kg/day, i.v.) given for 10 days and MMF (1.0 g/b.i.d.). CsA (8 mg/kg, in two divided doses) was
The number of patients experiencing an acute rejection started on post-operative day 11. Cs were only allowed after kidney transplantation has decreased considerin the case of MMF discontinuation, for the treatment ably during recent years. This is due to the effectiveness of acute rejection, and in the event of recurrence of of novel associations of immunosuppressive drugs. the primary glomerulonephritis.
Despite the well known side-effects of corticosteroids Results. All patients completed the entire 10-day ATG (Cs), these drugs continue to be included in such new course. Main side-effects included fever (>38°C ) and combinations. We have previously reported on the serum sickness, observed in 73 and 27% of the patients effectiveness of an immunosuppressive regimen based respectively. The incidence of acute rejection was 27% on rabbit antithymocyte globulin (ATG), cyclosporin (three of 11 patients). In two patients with acute microemulsion (CsA), and mycophenolate mofetil rejection, serum sickness was concomitantly diagnosed (MMF ), without Cs, in recipients of simultaneous and renal histology was partially compatible with kidney-pancreas transplants, in whom Cs administraimmune-complex disease. The remaining patient had tion had potentially detrimental effects [1] . Based on two episodes of low-grade rejection. All rejection episthe very low (7%) incidence of acute kidney rejection odes were rapidly reversed. Two patients (18%) were in our first study, the aim of the present study was to treated with ganciclovir for cytomegalovirus (CMV ) extend our observation to kidney transplant recipients. infection. Two patients (18%) are currently receiving
In addition, we investigated whether delaying the introCs for recurrence of the native glomerulonephritis and duction of CsA to the end of the ATG course would two rejection episodes respectively. All patients are further improve outcome, since both Cs and CsA could currently alive with functioning kidneys (average interfere with the mechanism of action of polyclonal follow-up of 8.4 months; average creatinine level of and monoclonal antilymphocyte globulins [2,3]. 128 mmol/l ). Conclusion. This pilot study suggests that ATG induc-consecutive patients (nine women and two men) between 39 sickness and renal dysfunction were compatible with and 64 years of age (average 48 years), who received a Banff 2b and Banff 2a rejection grade respectively primary (nine cadaver, one living unrelated, and one living ( Figures 1 and 2) . A rapid and complete normalization related) kidney transplant. For cadaveric transplantations, of renal function was observed in both patients after the cold ischaemic time was 23 h, ranging between 14 and ATG withdrawal and OKT3/plasma exchange therapy. 35 h. None of the patients was sensitized before transplanta-The patient with grade 2b rejection also required tion. Mean HLA-A, -B, and -DR mismatch between donor transient haemodialysis. As shown in Figure 1 , a signi- (ThymoglobulineA, IMTIX-Sangstat, Lyon, France), at a All patients are currently alive and have functioning starting intravenous dose of 1.5 mg/kg/day, was scheduled. transplants. Only one patient has a serum creatinine Doses of ATG were then monitored and adjusted according level above 150 mmol/l. This patient has never experito daily E-rosette test. ATG dose was adjusted to maintain enced an acute rejection episode or acute serum sickthe level of rosetting lymphocytes below 10% of the peripheral ness, but developed delayed graft function. The average mononucleated cells. MMF (CellCeptA, Hoffman La Roche, serum creatinine of all patients is 128 mmol/l, ranging Neuilly-sur-Seine, France) was started orally at a dose of 1.0 g/b.i.d. This dose was decreased or discontinued in the from 86 to 293. Only one patient has proteinuria case of adverse clinical or haematological events. CsA >1 g/day, secondary to the recurrence of focal glomer-(NeoralA, Novartis, Rueil-Malmaison, France) was intro-ular sclerosis. This last patient and the patient who duced on day 11 (after the end of the ATG course) at an was treated for two episodes of acute rejection are oral dose of 8 mg/kg, in two divided doses. Doses of CsA receiving Cs and tacrolimus treatment. Currently, were adjusted according to CsA blood trough levels, aiming two patients require treatment for hypertension. for 150 ng/ml (Cyclo-Trac SP, Sorin, France). Cs were started Throughout the follow-up period, MMF dosage was only in case of MMF discontinuation following the ATG reduced in four patients because of leukopenia, it course, and in the case of acute rejection or recurrence of remained unchanged in six patients and was withdrawn the primary glomerulonephritis. In patients suspected of in one patient.
experiencing an acute kidney rejection episode, a core renal biopsy was obtained to confirm the diagnosis and to graduate the histological features in accordance with the Banff classification [4] . Rejection episodes were treated with high-dose Discussion intravenous Cs (5, 5, 4, 3 and 2 mg/kg/day, over 5 consecutive days). Antiviral (herpes, cytomegalovirus (CMV )) pro-Despite not being aimed at efficacy, this pilot study phylaxis was not given and no patient received granulocyte suggests that the avoidance of Cs does not increase colony-stimulating factor to treat leukopenia. the incidence of acute rejection after primary renal transplantation. The need for anti-rejection treatment (27% of the patients) was similar (35%) to our historic Results controls receiving Cs, ATG induction, and delayed CsA [5] . None of these rejections impaired short-term renal function and/or induced permanent proteinuria. Follow-up ranged from 6 to 11 months (average 8.4). Despite delaying CsA administration to day 11, two Similarly, the absence of Cs-induced anti-inflammatory effects was not associated with an increased incidence patients (18%) required transient haemodialysis because of delayed graft function. The scheduled of delayed graft function (18%) or high levels of serum creatinine. On the other hand, patient clinical tolerance 10-day ATG course was given to all patients (an average of 24 vials per patient, ranging from 17 to 31). to ATG, without Cs and CsA, was poor (high incidence of fever and acute serum sickness) as compared to the Low-grade fever was observed in all patients during ATG therapy with 73% having a temperature Á38°C. pharmacovigilance profile of this drug when Cs and CsA are given concomitantly [6 ]. Three patients (27%) developed a typical acute serum sickness and in two of them, renal impairment was New immunosuppressive strategies have significantly reduced the incidence of acute rejection following involved. CMV infection was diagnosed in five patients (45%); however, only two patients required ganciclovir kidney transplantation to as low as 20% [7] [8] [9] .
Whether the actual primary end-point of these drug because of CMV disease. Three of the patients developed herpes labialis before CMV infection. One combinations must be 0% rejection remains unclear.
Severe side-effects and adverse events such as diabetes patient presented with a bacterial urinary tract infection. No other bacterial or fungal infections were and lymphoproliferative disorders seem to be more frequent than in the past. In addition, no true clinical observed. No patient experienced gastrointestinal sideeffects, diabetes or malignancy.
tolerance has yet been achieved and chronic immunosuppression is still required for maintaining the funcThree patients (27%) received an anti-rejection treatment; two of these also had serum sickness (on post-tion of most solid organ transplants.
Bacterial infections, gastrointestinal lesions, high operative day 10). Kidney lesions at the time of serum blood pressure, lipid abnormalities, glucose intolerance, excessive weight gain, cataracts, and osteoporosis are some of the well-known complications related to Cs treatment. Hence, immunosuppressive protocols aimed at avoiding Cs use may reduce the incidence of side-effects and eventually ameliorate the short-and long-term quality of life of the patients. On the contrary, avoidance of Cs may impair renal function by enhancing the ischaemia/reperfusion injury syndrome and/or by increasing the incidence of acute and chronic Unfortunately, no artery was observed in this third biopsy specimen in transplant animal models, Cs as well as CsA can (trichrome stain×200). At this time, serum creatinine level returned block the immunosuppressive action of agents such as to pre-rejection levels (150 mmol/l ) and no proteinuria was observed. CTLA4-Ig [12] and anti-CD40L [13] , and may have
